Login
Home
Charts
Search
Watchlist
Products

Symbiotec Pharmalab Ltd

SYMBIOTEC·NSE
₹1,147.15-0.77%Tue, 22 Sept '26 12:30
Industry:Pharmaceuticals Bulk Drugs & Formulation
Indices:

Symbiotec Pharmalab Ltd

SYMBIOTEC
NSE
₹1,147.15
-0.77%
|Tue, 22 Sept '26 12:30
SOICxStockScans Reports
Industry
Pharmaceuticals Bulk Drugs & Formulation
Indices
View
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹7,403Cr
Close
Close Price
₹1,152.10
Industry
Industry
Pharmaceuticals Bulk Drugs & Formulation
PE
Price To Earnings
64.18
PS
Price To Sales
8.52
Revenue
Revenue
₹869Cr
Rev Gr TTM
Revenue Growth TTM
—
PAT Gr TTM
PAT Growth TTM
—

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterJun 2025
Revenue
RevenueCr
203
Growth YoY
Revenue Growth YoY%
Expenses
ExpensesCr
145
Operating Profit
Operating ProfitCr
58
OPM
OPM%
28.5
Other Income
Other IncomeCr
3
Interest Expense
Interest ExpenseCr
5
Depreciation
DepreciationCr
11
PBT
PBTCr
45
Tax
TaxCr
15
PAT
PATCr
30
Growth YoY
PAT Growth YoY%
NPM
NPM%
14.7
EPS
EPS₹
5.5
QuarterJun 2025
Revenue
RevenueCr
203
Growth YoY
Revenue Growth YoY%
Expenses
ExpensesCr
145
Operating Profit
Operating ProfitCr
58
OPM
OPM%
28.5
Other Income
Other IncomeCr
3
Interest Expense
Interest ExpenseCr
5
Depreciation
DepreciationCr
11
PBT
PBTCr
45
Tax
TaxCr
15
PAT
PATCr
30
Growth YoY
PAT Growth YoY%
NPM
NPM%
14.7
EPS
EPS₹
5.5

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue
RevenueCr
633682567716752869
Growth
Revenue Growth%
7.7-16.926.44.915.7
Expenses
ExpensesCr
439552498545550631
Operating Profit
Operating ProfitCr
19413069171202238
OPM
OPM%
30.619.112.223.926.927.4
Other Income
Other IncomeCr
73674-6
Interest Expense
Interest ExpenseCr
62771625
Depreciation
DepreciationCr
222629394353
PBT
PBTCr
17310539132147153
Tax
TaxCr
482815315043
PAT
PATCr
124772510197110
Growth
PAT Growth%
-37.8-68.2312.9-4.413.4
NPM
NPM%
19.611.34.314.212.912.6
EPS
EPS₹
113.071.021.591.588.519.1
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue
RevenueCr
633682567716752869
Growth
Revenue Growth%
7.7-16.926.44.915.7
Expenses
ExpensesCr
439552498545550631
Operating Profit
Operating ProfitCr
19413069171202238
OPM
OPM%
30.619.112.223.926.927.4
Other Income
Other IncomeCr
73674-6
Interest Expense
Interest ExpenseCr
62771625
Depreciation
DepreciationCr
222629394353
PBT
PBTCr
17310539132147153
Tax
TaxCr
482815315043
PAT
PATCr
124772510197110
Growth
PAT Growth%
-37.8-68.2312.9-4.413.4
NPM
NPM%
19.611.34.314.212.912.6
EPS
EPS₹
113.071.021.591.588.519.1

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
111111111113
Reserves
ReservesCr
5105886117048041,137
Current Liabilities
Current LiabilitiesCr
225189228351473528
Non Current Liabilities
Non Current LiabilitiesCr
2328140229292104
Total Liabilities
Total LiabilitiesCr
7688159901,2951,5801,781
Current Assets
Current AssetsCr
423425400508493486
Non Current Assets
Non Current AssetsCr
3453905907871,0871,295
Total Assets
Total AssetsCr
7688159901,2951,5801,781
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
111111111113
Reserves
ReservesCr
5105886117048041,137
Current Liabilities
Current LiabilitiesCr
225189228351473528
Non Current Liabilities
Non Current LiabilitiesCr
2328140229292104
Total Liabilities
Total LiabilitiesCr
7688159901,2951,5801,781
Current Assets
Current AssetsCr
423425400508493486
Non Current Assets
Non Current AssetsCr
3453905907871,0871,295
Total Assets
Total AssetsCr
7688159901,2951,5801,781

Cash Flow

Consolidated
Standalone
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
174186918847175
Investing Cash Flow
Investing Cash FlowCr
-96-32-220-206-307-227
Financing Cash Flow
Financing Cash FlowCr
-79151462227836
Net Cash Flow
Net Cash FlowCr
-11-5319-16
Free Cash Flow
Free Cash FlowCr
87-55-155-22-261-50
CFO To PAT
CFO To PAT%
140.422.9281.9184.948.8158.9
CFO To EBITDA
CFO To EBITDA%
89.913.6100.5109.523.473.4
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
174186918847175
Investing Cash Flow
Investing Cash FlowCr
-96-32-220-206-307-227
Financing Cash Flow
Financing Cash FlowCr
-79151462227836
Net Cash Flow
Net Cash FlowCr
-11-5319-16
Free Cash Flow
Free Cash FlowCr
87-55-155-22-261-50
CFO To PAT
CFO To PAT%
140.422.9281.9184.948.8158.9
CFO To EBITDA
CFO To EBITDA%
89.913.6100.5109.523.473.4

Ratios

Consolidated
Standalone
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
7,403
Price To Earnings
Price To Earnings
64.2
Price To Sales
Price To Sales
8.5
Price To Book
Price To Book
5.7
EV To EBITDA
EV To EBITDA
31.2
Profitability Ratios
Profitability Ratios
GPM
GPM%
50.840.337.344.949.551.651.6
OPM
OPM%
30.619.112.223.926.927.427.4
NPM
NPM%
19.611.34.314.212.912.612.6
ROCE
ROCE%
31.416.25.614.512.011.611.6
ROE
ROE%
23.912.94.014.211.99.69.6
ROA
ROA%
16.29.52.57.86.16.26.2
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
7,403
Price To Earnings
Price To Earnings
64.2
Price To Sales
Price To Sales
8.5
Price To Book
Price To Book
5.7
EV To EBITDA
EV To EBITDA
31.2
Profitability Ratios
Profitability Ratios
GPM
GPM%
50.840.337.344.949.551.651.6
OPM
OPM%
30.619.112.223.926.927.427.4
NPM
NPM%
19.611.34.314.212.912.612.6
ROCE
ROCE%
31.416.25.614.512.011.611.6
ROE
ROE%
23.912.94.014.211.99.69.6
ROA
ROA%
16.29.52.57.86.16.26.2
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios

Documents — Symbiotec Pharmalab Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/as-81402ff72a835411a727a162.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/s82ptzfazei80wzpcdvx984y.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/wja8fzux3lnq6vy9y2sgxtng.pdf

Concall Transcript Summaries — Symbiotec Pharmalab Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3ASYMBIOTEC/transcript-notes/202606/as-81402ff72a835411a727a162.pdf

Simplify stock analysis with powerful tools and clear insights for confident, data-driven decisions.

support@stockscans.in
© StockScans by SOIC Technologies Pvt Ltd
349 A, Lodhi Road, Punjabi Bazar, New DelhiData provided by CMOTS Internet Technologies